Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities

被引：11

作者：

Song, Joo Y. ^{[1
]}

Dirnhofer, Stefan ^{[2
]}

Piris, Miguel A. ^{[3
]}

Quintanilla-Martinez, Leticia ^{[4
,5
,6
]}

Pileri, Stefano ^{[7
]}

Campo, Elias ^{[8
]}

机构：

[1] City Hope Natl Med Ctr, Dept Pathol, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] Univ Basel, Univ Hosp Basel, Inst Med Genet & Pathol, Basel, Switzerland

[3] Fdn Jimenez Diaz, Serv Anat Patol, CIBERONC, Madrid, Spain

[4] Eberhard Karls Univ Tubingen, Inst Pathol & Neuropathol, Tubingen, Germany

[5] Univ Hosp Tubingen, Comprehens Canc Ctr, Tubingen, Germany

[6] Image Guided & Funct Instructed Tumor Therapy, Cluster Excellence iFIT, Tubingen, Germany

[7] European Inst Oncol IRCCS, Div Hematopathol, Milan, Italy

[8] Univ Barcelona, Hosp Clin Barcelona, Inst Biomed Res August Pi I Sunyer IDIBAPS, Hematopathol Unit, Barcelona, Spain

来源：

VIRCHOWS ARCHIV | 2022年 / 482卷 / 1期

关键词：

Diffuse large B-cell lymphoma; Update; Classification; Molecular; Genomics; CENTRAL-NERVOUS-SYSTEM; PREVIOUSLY UNTREATED PATIENTS; EFFUSION-BASED LYMPHOMA; EXPRESSION PREDICTS; CD79B MUTATIONS; GENE-EXPRESSION; MYD88; L265P; R-CHOP; CLASSIFICATION; MYC;

D O I：

10.1007/s00428-022-03466-6

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogenous group of diseases and the most common subtype of non-Hodgkin lymphoma. In the past decade, there has been an explosion in molecular profiling that has helped to identify subgroups and shared oncogenic driving mechanisms. Since the 2017 World Health Organization (WHO) classification, additional studies investigating these genomic abnormalities and phenotypic findings have been reported. Here we review these findings in DLBCL and address the proposed changes by the 2022 International Consensus Classification.

引用

页码：179 / 192

页数：14

共 50 条

[21] Matrix Metalloproteinase-3 Producing Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Associated With Rheumatoid Arthritis
Nakayama-Ichiyama, Shoko
Yokote, Taiji
Hiraoka, Nobuya
Iwaki, Kazuki
Takayama, Ayami
Hirata, Yuji
Miyoshi, Takuji
Oka, Satoko
Akioka, Toshikazu
Makino, Shigeki
Tsuji, Motomu
Hanafusa, Toshiaki
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) : E731 - E732
[22] EBV-positive diffuse large B-cell lymphoma, not otherwise specified masking Richter syndrome
Lu, Susu
Zhao, Sha
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 613 - 615
[23] Developments over the last 60 years in diffuse large B-cell lymphomas
Linch, David
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (04) : 552 - 557
[24] Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Danilov, Alexey, V
Magagnoli, Massimo
Matasar, Matthew J.
ONCOLOGIST, 2022, 27 (01) : 57 - 66
[25] High Concordance of Gene Expression Profiling-correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma, Not Otherwise Specified
Hwang, Hee Sang
Park, Chan-Sik
Yoon, Dok Hyun
Suh, Cheolwon
Huh, Jooryung
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (08) : 1046 - 1057
[26] Targeted therapies in diffuse large B-cell lymphomas
Jullien, Maxime
Le Gouill, Steven
HEMATOLOGIE, 2021, 27 : 37 - 50
[27] Unresolved issues in diffuse large B-cell lymphomas
Murawski, Niels
Zwick, Carsten
Pfreundschuh, Michael
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (03) : 387 - 402
[28] Rituximab for the treatment of diffuse large B-cell lymphomas
Held, Gerhard
Poschel, Viola
Pfreundschuh, Michael
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) : 1175 - 1186
[29] Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment
Ta, Robert
Yang, David
Hirt, Christian
Drago, Thomas
Flavin, Richard
DIAGNOSTICS, 2022, 12 (05)
[30] The Histological Classification of Diffuse Large B-cell Lymphomas
Xie, Yi
Pittaluga, Stefania
Jaffe, Elaine S.
SEMINARS IN HEMATOLOGY, 2015, 52 (02) : 57 - 66

← 1 2 3 4 5 →